Gilat (GILT) Awarded Contract with a Potential of Over $50 Million to Supply Wavestream’s Gateway Solid State Power Amplifiers for Low Earth Orbit Constellation
- Microsoft (MSFT) Near Deal to Acquire Nuance (NUAN) - Report
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that its subsidiary Wavestream received an award estimated at more than $50M from a leading satellite operator to support the gateways for a Low Earth Orbit (LEO) broadband satellite constellation. Wavestream has been selected to supply Gateway Solid State Power Amplifiers (SSPAs) for the project.
Wavestream’s Gateway-Class PowerStream 160Ka SSPAs, designed specifically for networks using wide bandwidth uplinks and high order modulation schemes, were selected because of their best-in-class technical performance and their unmatched reliability in harsh environments, best addressing the stringent requirements of Non-Geostationary Satellite Orbit (NGSO) constellations.
"Wavestream has been selected as the vendor of choice to support the delivery of essential Gateways for the Low Earth Orbit satellite program," said Bob Huffman, Wavestream’s General Manager. "Wavestream's proven technological advantage, as well as our unmatched production capacity, make us a perfect supplier for the high volume of Ka-band Gateway-class SSPAs required for this constellation."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sanofi (SNY) Acquires Tidal Therapeutics for $160M Upfront and Up to $310M in Milestones
- Southwest (LUV) Pulls 30 Boeing (BA) 737 Max Jets From Schedule on Electric Issue, Sees Minimal Schedula Disruptions - Bloomberg
- Humanigen Inc. (HGEN) Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme